Patient-derived organoids and orthotopic xenografts of primary and recurrent gliomas represent relevant patient avatars for precision oncology

Anna Golebiewska, Ann‐Christin Hau, Anaïs Oudin, +38

Acta Neuropathologica

Oncologic ImagingPathologyOrthotopic XenograftsHigh-grade GliomasCancer Biology +23

Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes

Daniel Stieber, Anna Golebiewska, Lisa Evers, +10

Acta Neuropathologica

Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells

Anna Golebiewska, Sébastien Bougnaud, Daniel Stieber, +7

Brain

Tumor InnervationEndothelial CellsPathologyHigh-grade GliomasCancer Biology +20

Molecular crosstalk between tumour and brain parenchyma instructs histopathological features in glioblastoma

Sébastien Bougnaud, Anna Golebiewska, Anaïs Oudin, +16

Oncotarget

Tumor InnervationEndothelial CellsPathologyGliomaTumor Biology +20

iTRAQ-based Proteomics Profiling Reveals Increased Metabolic Activity and Cellular Cross-talk in Angiogenic Compared with Invasive Glioblastoma Phenotype

Uroš Rajčević, Kjell Petersen, Jaco C. Knol, +11

Molecular & Cellular Proteomics

αB-Crystallin Is Elevated in Highly Infiltrative Apoptosis-Resistant Glioblastoma Cells

Dorota Goplen, Sébastien Bougnaud, Uroš Rajčević, +8

American Journal Of Pathology

GliomaApoptosisCell DeathAnti-cancer AgentMedicine +2

Colorectal cancer derived organotypic spheroids maintain essential tissue characteristics but adapt their metabolism in culture

Uroš Rajčević, Jaco C. Knol, Sander R. Piersma, +8

Proteome Science

AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer

Agnete S. T. Engelsen, Katarzyna Wnuk-Lipińska, Sébastien Bougnaud, +25

iScience

Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM)

Kevin Demeure, Fred Fack, Elodie Duriez, +7

Molecular & Cellular Proteomics

Combination of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung.

Murray Yule, Kjersti Davidsen, Magnus Bloe, +15

Journal of Clinical Oncology

Innate Immune SystemImmune RegulationImmunologyPathologyImmunoediting +24